FAIM
BIIB icon

Financial Advocates Investment Management’s Biogen BIIB Stock Holding History

Financial Advocates Investment Management’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-903
Closed -$217K – 740
2021
Q4 		$217K Sell
903
-3,928
-81% -$1.01M 0.01% 711
2021
Q3 		$1.37M Buy
4,831
+3,774
+357% +$1.24M 0.09% 252
2021
Q2 		$366K Buy
1,057
+119
+13% +$36K 0.02% 555
2021
Q1 		$262K Buy
+938
New +$253K 0.02% 645

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Financial Advocates Investment Management's BIIB Position: Q1 2022 in Review

Financial Advocates Investment Management sold out of Biogen (BIIB) in Q1 2022, closing a stake of 903 shares — an estimated $217K sold.

Financial Advocates Investment Management first reported a position in BIIB in Q1 2021 and held it in 4 quarters. The position peaked at $1.37M in Q3 2021. 953 funds tracked by Wall St. Rank hold BIIB as of Q1 2022.

  • Financial Advocates Investment Management reported no remaining Biogen position as of Q1 2022 after selling out during the quarter.
  • Financial Advocates Investment Management sold 903 Biogen shares in Q1 2022, an estimated $217K.
  • Financial Advocates Investment Management first reported a position in Biogen in Q1 2021 and held it in 4 quarters.
  • Financial Advocates Investment Management's Biogen position peaked at $1.37M in Q3 2021.
  • 953 funds tracked by Wall St. Rank held Biogen as of Q1 2022.

Based on Financial Advocates Investment Management's 13F filing for Q1 2022, filed 11 May 2022.